{"id":"factor-concentrates","safety":{"commonSideEffects":[{"rate":null,"effect":"Inhibitor development (alloimmunization)"},{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL1235246","moleculeType":"Small molecule","molecularWeight":"523.69"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Factor concentrates are purified or recombinant blood coagulation factors (such as Factor VIII, Factor IX, Factor V, fibrinogen, or prothrombin complex concentrates) that are administered intravenously to patients with inherited or acquired deficiencies. They work by restoring the missing or dysfunctional clotting factors in the coagulation cascade, enabling normal thrombin generation and fibrin clot formation to prevent or treat bleeding episodes.","oneSentence":"Factor concentrates replace or supplement deficient clotting factors to restore hemostatic function in patients with bleeding disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:36.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A (Factor VIII deficiency)"},{"name":"Hemophilia B (Factor IX deficiency)"},{"name":"Other inherited factor deficiencies"},{"name":"Acquired coagulation factor deficiencies"}]},"trialDetails":[{"nctId":"NCT07285460","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-18","conditions":"Hemophilia","enrollment":85},{"nctId":"NCT07101926","phase":"","title":"Monitoring of Anti-TFPI in Hemophilia","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-10-23","conditions":"Hemophilia, Rebalancing Agents, Prophylaxis","enrollment":11},{"nctId":"NCT06998524","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-06-27","conditions":"Von Willebrand Disease, Type 3","enrollment":75},{"nctId":"NCT06883240","phase":"","title":"An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-29","conditions":"Von Willebrand Disease, Type 3","enrollment":40},{"nctId":"NCT07094087","phase":"PHASE3","title":"Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-09-15","conditions":"Complex Cardiovascular Surgery With Cardiopulmonary Bypass","enrollment":200},{"nctId":"NCT07439055","phase":"PHASE2, PHASE3","title":"Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chulalongkorn University","startDate":"2025-06-01","conditions":"Hemophilia A Patient","enrollment":18},{"nctId":"NCT07410130","phase":"","title":"Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03","conditions":"Von Willebrand Disease (VWD), Inherited Bleeding Disorders in Children, Pediatric Hemostatic Disorders","enrollment":25},{"nctId":"NCT05662319","phase":"PHASE3","title":"A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-02-01","conditions":"Hemophilia","enrollment":91},{"nctId":"NCT04670965","phase":"","title":"Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04","conditions":"Bone Loss","enrollment":20},{"nctId":"NCT04964466","phase":"","title":"Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-08-31","conditions":"Bone Loss","enrollment":5},{"nctId":"NCT04867837","phase":"PHASE3","title":"Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor","status":"RECRUITING","sponsor":"Octapharma","startDate":"2021-09-01","conditions":"Acute Major Bleeding","enrollment":260},{"nctId":"NCT03695978","phase":"","title":"Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients","status":"RECRUITING","sponsor":"Octapharma","startDate":"2018-02-13","conditions":"Haemophilia A","enrollment":200},{"nctId":"NCT06145373","phase":"PHASE4","title":"A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-03-01","conditions":"Hemophilia A","enrollment":20},{"nctId":"NCT05523297","phase":"PHASE3","title":"Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery","status":"COMPLETED","sponsor":"Octapharma","startDate":"2022-11-30","conditions":"Bleeding Cardiac Surgery Patients","enrollment":420},{"nctId":"NCT07099313","phase":"","title":"Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia","status":"RECRUITING","sponsor":"Investigación en Hemofilia y Fisioterapia","startDate":"2025-07-31","conditions":"Hemophilia","enrollment":114},{"nctId":"NCT06144112","phase":"PHASE4","title":"Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery","status":"NOT_YET_RECRUITING","sponsor":"Konkuk University Medical Center","startDate":"2025-09-01","conditions":"Liver Diseases","enrollment":92},{"nctId":"NCT06869200","phase":"NA","title":"Study on the Use of a Concentrated Growth Factor Preparation Kit for the Treatment of Knee Osteoarthritis","status":"ENROLLING_BY_INVITATION","sponsor":"Guangdong Hongzhi Health Technology","startDate":"2025-03","conditions":"Knee Osteoarthritis","enrollment":104},{"nctId":"NCT05667805","phase":"PHASE4","title":"Coagulation in Cirrhosis","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2023-01-19","conditions":"Liver Cirrhosis","enrollment":400},{"nctId":"NCT02460458","phase":"","title":"Type 3 Von Willebrand International Registries Inhibitor Prospective Study","status":"COMPLETED","sponsor":"Fondazione Angelo Bianchi Bonomi","startDate":"2012-11-05","conditions":"Type 3 Von Willebrand's Disease","enrollment":265},{"nctId":"NCT04053699","phase":"","title":"Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment","status":"COMPLETED","sponsor":"Octapharma","startDate":"2019-06-25","conditions":"Von Willebrand Diseases","enrollment":56},{"nctId":"NCT04621916","phase":"PHASE4","title":"Preventing Inhibitor Recurrence Indefinitely","status":"UNKNOWN","sponsor":"Children's Hospital Los Angeles","startDate":"2020-09-21","conditions":"Hemophilia A, Immune Tolerance","enrollment":52},{"nctId":"NCT03533504","phase":"","title":"Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2018-05-09","conditions":"Hemophilia A, Hemophilia B","enrollment":1000},{"nctId":"NCT02740335","phase":"PHASE3","title":"Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-06-08","conditions":"Significant Bleeding Risk","enrollment":208},{"nctId":"NCT05738642","phase":"NA","title":"Evaluation of the Efficacy of Early Bunching of a FF-PCC in Patients With Severe Traumatic Hemorrhage","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-01","conditions":"Trauma","enrollment":380},{"nctId":"NCT04534751","phase":"PHASE4","title":"Factor In the Initial Resuscitation of Severe Trauma 2 Patients","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-04-01","conditions":"Traumatic Hemorrhage, Coagulopathy, Massive Hemorrhage","enrollment":350},{"nctId":"NCT05281185","phase":"PHASE4","title":"Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2021-07-01","conditions":"Severe Hemophilia A Without Inhibitor","enrollment":15},{"nctId":"NCT03358836","phase":"","title":"Joint Health Study","status":"COMPLETED","sponsor":"Bloodworks","startDate":"2017-11-15","conditions":"Hemophilia B","enrollment":8},{"nctId":"NCT03417245","phase":"PHASE3","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-03-01","conditions":"Hemophilia A, Hemophilia B","enrollment":120},{"nctId":"NCT05188768","phase":"NA","title":"Growth Factors in the Localized Gingival Recessions Treatment","status":"COMPLETED","sponsor":"Bulent Ecevit University","startDate":"2015-07","conditions":"Localized Gingival Recession","enrollment":18},{"nctId":"NCT01051076","phase":"NA","title":"Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2009-11-03","conditions":"Severe Hemophilia A","enrollment":3},{"nctId":"NCT03784794","phase":"NA","title":"Patient Blood Management for Massive Obstetric Hemorrhage","status":"COMPLETED","sponsor":"Angel Augusto Perez Calatayud","startDate":"2018-11-01","conditions":"Post Partum Hemorrhage, Fibrinogenolysis; Hemorrhage, Fibrinogen; Deficiency, Acquired","enrollment":100},{"nctId":"NCT01128881","phase":"PHASE4","title":"IMMUNINE Pre-Treatment Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2010-05-31","conditions":"Hemophilia B","enrollment":57},{"nctId":"NCT04851002","phase":"NA","title":"Effects of Different Centrifuged Platelet Concentrates on Bone Remodelling Around Dental Implants","status":"COMPLETED","sponsor":"Muhammet Atilgan","startDate":"2019-10-03","conditions":"Edentulous Jaw, Bone Loss, Alveolar, Resorption, Bone","enrollment":40},{"nctId":"NCT04805463","phase":"NA","title":"Different Platelet Concentrates After Gingivectomy and Gingivoplasty Evaluation of Its Effect on Early Wound Healing.","status":"COMPLETED","sponsor":"Inonu University","startDate":"2020-01-01","conditions":"Wound Heal, Gingival Overgrowth, Gingival Enlargement","enrollment":19},{"nctId":"NCT04567199","phase":"","title":"Influence of Cytosorb on Amount of Catecholamine and Mortality in Sepsis","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2018-12-01","conditions":"Sepsis, Septic Shock, Cytokine Storm","enrollment":86},{"nctId":"NCT01051544","phase":"NA","title":"Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2009-09-25","conditions":"Severe Hemophilia A","enrollment":""},{"nctId":"NCT03715348","phase":"PHASE2","title":"Trial of PCC Versus FFP in Patients Undergoing Heart Surgery","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2019-03-01","conditions":"Bleeding, Surgery, Transfusion","enrollment":50},{"nctId":"NCT04114643","phase":"PHASE2","title":"Factor Replacement in Surgery","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2019-09-24","conditions":"Bleeding in Cardiac Surgery","enrollment":103},{"nctId":"NCT04261634","phase":"NA","title":"CGF and PRF in the Gingival Recessions Treatment","status":"COMPLETED","sponsor":"Bulent Ecevit University","startDate":"2015-05","conditions":"Gingival Recession","enrollment":18},{"nctId":"NCT04237766","phase":"NA","title":"Movement Visualization in Patients With Hemophilic Arthropathy","status":"UNKNOWN","sponsor":"Real Fundación Victoria Eugenia","startDate":"2020-05-01","conditions":"Hemophilia","enrollment":140},{"nctId":"NCT04151147","phase":"NA","title":"Effect of CGF on Frequency of Alveolar Osteitis Following Partially Erupted Mandibular Third Molar Surgery","status":"COMPLETED","sponsor":"Ege University","startDate":"2018-01-02","conditions":"Alveolar Osteitis, Impacted Tooth","enrollment":70},{"nctId":"NCT03009591","phase":"NA","title":"Fascial Therapy in Elbow Hemophilic Arthropathy","status":"COMPLETED","sponsor":"Real Fundación Victoria Eugenia","startDate":"2018-02-12","conditions":"Hemophilia","enrollment":69},{"nctId":"NCT03313531","phase":"","title":"Evaluation of a Standardized Protocol for Thrombin Generation Assay","status":"COMPLETED","sponsor":"Lund University","startDate":"2017-04-15","conditions":"Hemophilia A","enrollment":9},{"nctId":"NCT03756948","phase":"NA","title":"Viscoelastic Tests-Guided Therapy In Liver Transplantation","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2007-01-01","conditions":"Liver Transplant; Complications, Bleeding, Hemostatic Disorder","enrollment":237},{"nctId":"NCT01064284","phase":"PHASE4","title":"Survey of Inhibitors in Plasma-Product Exposed Toddlers","status":"COMPLETED","sponsor":"Fondazione Angelo Bianchi Bonomi","startDate":"2010-01","conditions":"Hemophilia A","enrollment":303},{"nctId":"NCT03231137","phase":"PHASE4","title":"Socket Augmentation Using Platelet Concentrates, Atorvastatin Gel or Combination","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2012-06-16","conditions":"Alveolar Socket Preservations","enrollment":50},{"nctId":"NCT00839202","phase":"NA","title":"Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2006-09","conditions":"Hemophilia A","enrollment":7},{"nctId":"NCT01656330","phase":"PHASE1","title":"A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-07","conditions":"Healthy","enrollment":35},{"nctId":"NCT01545635","phase":"PHASE3","title":"RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma","status":"TERMINATED","sponsor":"Medical University Innsbruck","startDate":"2012-03","conditions":"Major Trauma","enrollment":100},{"nctId":"NCT01705808","phase":"PHASE3","title":"Administration of Protein C Concentrates in Adult Critically Ill Septic Patients","status":"TERMINATED","sponsor":"Università Vita-Salute San Raffaele","startDate":"2012-09","conditions":"Sepsis","enrollment":""},{"nctId":"NCT01411670","phase":"PHASE2","title":"Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock.","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2011-01","conditions":"Sepsis, Septic Shock","enrollment":60},{"nctId":"NCT02074358","phase":"PHASE1","title":"A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Anticoagulation","enrollment":43},{"nctId":"NCT02479087","phase":"PHASE4","title":"Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2015-01","conditions":"Hemophilia A","enrollment":20},{"nctId":"NCT02385734","phase":"NA","title":"Concentrated Growth Factor in the Treatment of Gingival Recessions","status":"COMPLETED","sponsor":"Bulent Ecevit University","startDate":"2013-04","conditions":"Gingival Recession","enrollment":20},{"nctId":"NCT01505946","phase":"","title":"Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors","status":"UNKNOWN","sponsor":"Grifols Italia S.p.A","startDate":"2012-03","conditions":"Severe Hemophilia A With Inhibitor","enrollment":25},{"nctId":"NCT01269138","phase":"","title":"Treatment of Inherited Factor VII Deficiency","status":"COMPLETED","sponsor":"University of L'Aquila","startDate":"2007-01","conditions":"Factor VII Deficiency","enrollment":223},{"nctId":"NCT00212472","phase":"NA","title":"International Immune Tolerance Study","status":"TERMINATED","sponsor":"New York Presbyterian Hospital","startDate":"2002-07","conditions":"Hemophilia A With Inhibitors","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1548,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"factor concentrates","genericName":"factor concentrates","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Factor concentrates replace or supplement deficient clotting factors to restore hemostatic function in patients with bleeding disorders. Used for Hemophilia A (Factor VIII deficiency), Hemophilia B (Factor IX deficiency), Other inherited factor deficiencies.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}